Clinical biopharmaceutical company: Forte Biosciences, Inc. (FBRX)

Forte Biosciences, Inc. (NASDAQ: FBRX), founded in 2007 and headquartered in Torrance, California, is a clinical dermatology company with 9 full-time employees.

The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/fbrx.html

Forte Biosciences (FBRX) US Equities Encyclopedia

Forte Biosciences Inc. is a clinical Biopharmaceutical Company 。 It is developing a live biological therapeutic drug FB-401, which has completed phase 1/2a clinical trials for the treatment of inflammatory skin diseases in children with atopic dermatitis. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/fbrx.html

Forte Biosciences is a clinical stage biopharmaceutical company focusing on dermatology. Forte's leading product, FB-401, is an active biological therapeutic agent developed in cooperation with the National Institutes of Health ("NIH") and the National Institute of Allergy and Infectious Diseases ("NIAID") to treat inflammatory skin diseases. Skin is a complex barrier organ, which is characterized by complex interactions between microbial communities and host tissues through signals provided by the innate immune system and adaptive immune system. Exposure to various endogenous and exogenous factors will affect the system balance and may lead to inflammatory skin diseases, including infection, allergy or autoimmune diseases. Microbiology and dermatology researchers have identified and characterized microorganisms present on the skin to evaluate the contribution of bacteria to skin health and skin diseases. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/fbrx.html

On June 15, 2020, Forte Biosciences, Inc. (NASDAQ: FBRX), a clinical biopharmaceutical company, announced the completion of the merger with Tocagen Inc. According to the merger, Forte's shareholders have become the majority shareholders of Tocagen, and Tocagen shares Delisting 。 The company will be led by Dr. Paul Wagner. The newly merged company, named Forte Biosciences, will start trading in the NASDAQ capital market on June 16, 2020, with the transaction code of "FBRX". The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/fbrx.html

Forte Biosciences is developing an active biological therapeutic agent FB-401, which has completed Phase I/IIa clinical trial for the treatment of inflammatory skin diseases in children with atopic dermatitis. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/fbrx.html

Forte Biosciences (FBRX) US equity investment

• reference material: